A5042267348- Veterinary Oncology Research
- Infectious Diseases and Mycology
- Virus-based gene therapy research
- Sarcoma Diagnosis and Treatment
- Tumors and Oncological Cases
- Oral and Maxillofacial Pathology
- Microbial infections and disease research
- Salivary Gland Tumors Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Bone Tumor Diagnosis and Treatments
- Veterinary Orthopedics and Neurology
- Cell Adhesion Molecules Research
- Mast cells and histamine
- Peptidase Inhibition and Analysis
- Anesthesia and Pain Management
- Lymphoma Diagnosis and Treatment
- Soft tissue tumor case studies
- Cancer Research and Treatments
- Ear and Head Tumors
- Cancer, Stress, Anesthesia, and Immune Response
- Angiogenesis and VEGF in Cancer
- Cancer and Skin Lesions
- Human-Animal Interaction Studies
- Protease and Inhibitor Mechanisms
- Veterinary Pharmacology and Anesthesia
University of Milan
2016-2025
University of Veterinary Medicine
2016
Mylan (Switzerland)
2016
Clinica Mediterranea
2011
Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini"
2008
University of Turin
2008
Ospedale Maggiore di Lodi
2006
To compare the Kiupel (2 categories) and Patnaik (3 histologic grading systems for predicting presence of metastasis at time initial examination in dogs with cutaneous mast cell tumors (MCTs).Retrospective case series.386 client-owned MCTs.Medical records newly diagnosed, histologically confirmed MCTs that had undergone complete clinical staging were reviewed histopathologic data.All grade 1 (n = 52) classified as low-grade MCTs, all 3 (43) high-grade MCTs. Of 291 2 243 (83.5%) tumors, 48...
Perivascular wall tumors (PWTs) are defined as neoplasms deriving from mural cells of blood vessels, excluding the endothelial lining. The spectrum human cutaneous PWT includes glomus tumor, hemangiopericytoma (HEP), myopericytoma, angioleiomyoma/sarcoma, angiomyofibroblastoma, and angiofibroma. purpose this study was to revise clinical presentation, cytology, histopathology, immunohistology canine with cytology typical HEP. Diagnosis established on basis vascular growth patterns (staghorn,...
Abstract Objective —To determine factors predicting survival in dogs with high-grade multicentric lymphoma. Design —Retrospective cohort study. Animals —127 lymphoma evaluated at 4 veterinary hospitals from 2000 to 2009. Procedures —Records were reviewed identify completely staged treated chemotherapy. Data collected included signalment, history, hematologic findings, tumor characteristics, treatment, and outcome. Long-term was defined as surviving > 2 years after diagnosis. Variables...
In the clinical staging of cutaneous mast cell tumors (cMCT), diagnosis metastasis is controversial based on cytological examination lymph nodes, spleen, liver, bone marrow, and blood.To define prognostic role ultrasound-guided cytology spleen liver in cMCT. The results evaluation were compared relation with survival time.Fifty-two client-owned dogs a cMCT.Selection cases was to detect infiltration at distant sites. Kaplan Meier method used compare without (log-rank test P < .05).Ten cMCT...
Metastasis to regional lymph nodes (RLNs) in dogs with cutaneous mast cell tumour (cMCT) has been correlated shortened survival time and higher risk of spread distant sites. In the present study, extirpation non-palpable or normal-sized RLNs was included surgical management cMCT dogs. Correlations between histological nodal status (HN0-3) variables were analysed. Ninety-three single without metastasis that underwent wide excision primary RLN included. The association HN (HN0 vs > 0; HN0-1...
Background: Fine‐needle aspiration cytology (FNAC) is commonly used as a diagnostic procedure to evaluate superficial and deep masses in animals. However, few studies have addressed the accuracy of FNAC evaluation cutaneous subcutaneous clinical setting. Objective: The purpose this study was compare compared with histopathology diagnosis from dogs cats. Methods: Cytologic histopathologic specimens obtained between 1999 2003 292 palpable 242 50 cats were retrospectively evaluated. samples by...
Objective— To evaluate recurrence rate and disease‐free interval (DFI) of dogs with low‐grade soft tissue spindle cell sarcoma the extremities treated by marginal excision. Study Design— Retrospective study. Animals— Dogs (n=35) sarcoma. Methods— Medical records were reviewed that had surgical resection at or distal to elbow stifle included. Results— Histopathologic margins dirty (12 dogs), clean but close (12), (11). Follow‐up after surgery occurred from 210 2202 days (minimum, 180 days)....
To describe clinical characteristics, treatment, and outcome of dogs with inflammatory carcinoma (IC) identify patient-, tumor-, treatment-related factors associated overall survival time.Retrospective case series.43 client-owned dogs.Records a diagnosis IC that had histologic evidence dermal lymphatic invasion were reviewed. Data on staging, toxicoses, response, time retrieved. Results-26 (60%) primary 17 (40%) secondary IC. Thirty-five (81%) distant metastases 2 (5%) local at the initial...
Chronic lymphocytic leukemia (CLL) is a hematologic disorder in dogs, but studies on prognostic factors and clinical outcome are lacking. In people, several have been identified currently used to manage patients determine therapy.The aim of the study was if immunophenotype neoplastic cells predicts survival canine CLL.Retrospective study.Forty-three dogs with CLL.Records final diagnosis CLL were reviewed. For each included dog, CBC, blood smear for microscopic reevaluation, immunophenotyping...
Lymph node (LN) metastasis in canine cutaneous mast cell tumours (cMCTs) is a well-known negative prognostic factor. The role of lymphadenectomy the treatment stage II disease remains controversial because its uncertain therapeutic benefit. Aim this retrospective study was to investigate impact on tumour control and survival for dogs with cMCTs. Dogs firstly occurring, histologically confirmed cMCT LN undergoing resection primary medical thereafter were retrospectively enrolled. classified...
Abstract Lymph node (LN) metastasis is a negative prognostic factor in dogs with cutaneous mast cell tumours (cMCTs). While elective lymphadenectomy of metastatic LNs improves outcome, the benefit adjuvant medical therapy early (HN2) debated. The aim this retrospective multicentre study was to evaluate therapeutic following surgical removal primary low‐grade cMCT (Patnaik grade 1‐2 and Kiupel low‐grade) HN2 by analysing survival rates patterns recurrence. Seventy‐three were included: 42...
Nano-and microsized extracellular vesicles (EVs) are naturally occurring cargo-bearing packages of regulatory macromolecules, and recent studies increasingly showing that EVs responsible for physiological intercellular communication.Nanoparticles encapsulating anti-tumor theranostics represent an attractive "exosome-interfering" strategy cancer therapy.Methods: Herein, by labeling plasma-derived with indocyanine green (ICG) following their biodistribution in vivo ex imaging, we demonstrate...
Abstract Background Canine subcutaneous mast cell tumours (ScMCTs) reportedly have a good prognosis. However, biomarkers that can be used to predict outcome are currently limited. Methods A multicentre prospective study was conducted identify new prognostic markers. Dogs with first occurrence of ScMCT were enrolled upon primary tumour removal and regional lymphadenectomy. In the absence metastasis, dogs monitored, while overtly metastatic lymph nodes (histological node 3, HN3) received...
Abstract Objective To report the outcomes associated with sentinel lymph nodes (SLN) detection and extirpation guided by radionuclide methylene blue injections in dogs cutaneous subcutaneous mast cell tumors (MCT). Study design Clinical prospective cohort study. Animals Thirty client‐owned MCT amenable to wide‐margin excision, without evidence of distant metastasis abnormal regional (RLN). Methods Technetium‐99 m were injected peritumorally. Dogs underwent preoperative γ‐camera scintigraphy...
Abstract Background The therapeutic role and prognostic relevance of lymphadenectomy in mast cell tumor (MCT) has historically been evaluated on regional rather than sentinel lymph nodes. Hypothesis/Objectives To update information about the association histological nodal (HN) classes with clinical outcome dogs MCT after excision extirpation normal‐sized nodes (SLN) guided by radiopharmaceutical. Animals Ninety‐four histologically‐confirmed treatment‐ naïve (71 cutaneous, 22 subcutaneous 1...
Background/Objectives: Mast cell tumors (MCTs) are the second most common malignant neoplasms in dogs. Histopathological grading and clinical staging main tools for estimating biological behavior disease extent; thus, both essential therapeutic decision-making prognostication. However, of MCTs dogs is variable, it sometimes deviates from expectations. In a previous study, we identified 12 transcripts whose expression profile allowed clear distinction between Kiupel low-grade high-grade...
Abstract Objective The first aim was to describe the incidence and severity of surgical complications following peripheral lymphadenectomy in dogs. second compare three techniques: unassisted lymphadenectomy, intraoperative guidance by methylene blue dye alone (MB) or a combination γ‐probe MB (γ‐MB). third assess whether number, palpability, site lymph nodes (LNs) influenced complications. Study design Retrospective multicenter study. Sample population Lymphadenectomies ( n = 201) from 163...
Canine soft tissue sarcomas (STSs) are locally aggressive mesenchymal tumors with variable recurrence rates, and often, their therapy is limited to surgical excision. CD117 (KIT) a tyrosine kinase receptor involved in cell growth cancer development. c-kit proto-oncogene mutations have been reported be associated prognosis response human canine cancers. However, expression rarely investigated STSs. This study aims assess different Spontaneous STSs were surgically removed, fixed, routinely...
Background Canine cutaneous perivascular wall tumors (c‐ PWT ) are soft tissue sarcomas recently identified when hemangiopericytomas were reclassified. No previous clinical data available for c‐ . Hypothesis/Objectives To define the behavior and prognostic role of pathological variables in a homogeneous population Animals Fifty‐five c‐PWT 53 client‐owned dogs at first presentation undergoing surgery. Methods Retrospective case series. The endpoint was relapse tumor (local and/or distant)....
Canine perivascular wall tumors (cPWTs) arise from vascular mural cells and are included among soft tissue sarcomas (STSs). Most prognostic studies performed on canine STSs as a general group regardless of their specific histotype. The aim this study was to identify pathological parameters profiles with impact for cutaneous/subcutaneous cPWTs. Anatomical location, type growth, surgical margins, size depth the tumor were collected in 56 association between each pair variables evaluated by...
Background Distant metastases in dogs with cutaneous mast cell tumors (cMCT) are rare and incurable. The aims of this prospective study were to clarify the clinico‐pathological features stage IV cMCTs identify possible prognostic factors for progression‐free interval (PFI) survival time (ST). Material methods Dogs eligible recruitment if they had a previously untreated, histologically confirmed cMCT underwent complete staging demonstrating disease. uniformly followed‐up, whereas treatment...
Haemangiosarcoma (HSA) has an aggressive biological behaviour and carries a poor prognosis, with less than 10% of treated dogs surviving longer 1 year. In this retrospective study varied metronomic chemotherapy (MC) regimen preceded by adjuvant doxorubicin-based maximum-tolerated dose (MTDC) was compared MTDC, in terms efficacy [time to metastasis, (TTM) survival time (ST)] safety biologically HSA. Dogs were eligible if they had no metastasis after MTDC received either further or MC...
<h3>Background</h3> Pet dogs spontaneously develop lymphoma. An anthracycline-based multidrug chemotherapy regimen represents the treatment cornerstone; however, cure is rarely achieved. We have been treating with B-cell lymphoma an autologous vaccine (APAVAC®) and CHOP-based since 2011. <h3>Methods</h3> To better characterize safety efficacy of APAVAC®, to find best candidates for immunotherapy, we designed a retrospective study on all treated chemo-immunotherapy date compared them those...